Short-term Biodistribution and Clearance of Intravenously Administered Silica Nanoparticles

Overview

Journal Toxicol Rep

Date 2019 Jan 10

PMID 30622900

Citations 19

Authors

Nadia Waegeneers

Anne Brasseur

Elke Van Doren

Sara Van der Heyden

Pieter-Jan Serreyn

Luc Pussemier

Jan Mast

Yves-Jacques Schneider

Ann Ruttens

Stefan Roels

Affiliations

Soon will be listed here.

Abstract

Recently, concerns have been raised about potential adverse effects of synthetic amorphous silica, commonly used as food additive (E551), since silica nanoparticles have been detected in food containing E551. We examined the biodistribution and excretion in female Sprague-Dawley rats of NM-200, a well characterized nanostructured silica representative for food applications. A single intravenous injection of NM-200 was applied at a dose of 20 mg/kg, followed by autopsy after 6 and 24 h. The main organs where silicon accumulated were liver and spleen. The silicon concentration significantly decreased in spleen between 6 and 24 h. In liver the tendency was the same but the effect was not significant. This could be due to clearance of the spleen to the liver via the splenic vein, while liver clearance takes more time due to hepatic processing and biliary excretion. In treated animals the liver showed in addition a prominent increase of macrophages between both evaluation moments. Within the first 24 h, silicon was mainly excreted through urine. Further studies are necessary to evaluate the toxicokinetics of different types of silica nanomaterials at lower exposure doses in order to be able to predict kinetics and toxicity of silica nanoparticles depending on their physicochemical characteristics.

Citing Articles

Comparative Assessment of Cellular Responses to Microscale Silica Morphologies in Human Gastrointestinal Cells: Insights for Occupational Health.

Yamin M, Liu J, Sayes C Int J Environ Res Public Health. 2024; 21(10).

PMID: 39457349 PMC: 11508045. DOI: 10.3390/ijerph21101376.

Re-evaluation of silicon dioxide (E 551) as a food additive in foods for infants below 16 weeks of age and follow-up of its re-evaluation as a food additive for uses in foods for all population groups.

Younes M, Aquilina G, Castle L, Degen G, Engel K, Fowler P EFSA J. 2024; 22(10):e8880.

PMID: 39421729 PMC: 11483555. DOI: 10.2903/j.efsa.2024.8880.

State of the Art of Silica Nanoparticles: An Overview on Biodistribution and Preclinical Toxicity Studies.

Yu J, Dan N, Eslami S, Lu X AAPS J. 2024; 26(3):35.

PMID: 38514482 DOI: 10.1208/s12248-024-00906-w.

Autophagy and Biomaterials: A Brief Overview of the Impact of Autophagy in Biomaterial Applications.

Pirmoradi L, Shojaei S, Ghavami S, Zarepour A, Zarrabi A Pharmaceutics. 2023; 15(9).

PMID: 37765253 PMC: 10536801. DOI: 10.3390/pharmaceutics15092284.

Synthesis and Characterization of Silica, Silver-Silica, and Zinc Oxide-Silica Nanoparticles for Evaluation of Blood Biochemistry, Oxidative Stress, and Hepatotoxicity in Albino Rats.

Ali A, Saeed S, Hussain R, Afzal G, Siddique A, Parveen G ACS Omega. 2023; 8(23):20900-20911.

PMID: 37332821 PMC: 10269246. DOI: 10.1021/acsomega.3c01674.

References

Klemens P, Heumann K . Development of an ICP-HRIDMS method for accurate determination of traces of silicon in biological and clinical samples. Fresenius J Anal Chem. 2002; 371(6):758-63. DOI: 10.1007/s002160100996. View

Opanasopit P, Nishikawa M, Hashida M . Factors affecting drug and gene delivery: effects of interaction with blood components. Crit Rev Ther Drug Carrier Syst. 2003; 19(3):191-233. DOI: 10.1615/critrevtherdrugcarriersyst.v19.i3.10. View

So S, Jang I, Han C . Effect of micro/nano silica particle feeding for mice. J Nanosci Nanotechnol. 2009; 8(10):5367-71. DOI: 10.1166/jnn.2008.1347. View

Nishimori H, Kondoh M, Isoda K, Tsunoda S, Tsutsumi Y, Yagi K . Silica nanoparticles as hepatotoxicants. Eur J Pharm Biopharm. 2009; 72(3):496-501. DOI: 10.1016/j.ejpb.2009.02.005. View

Nishimori H, Kondoh M, Isoda K, Tsunoda S, Tsutsumi Y, Yagi K . Histological analysis of 70-nm silica particles-induced chronic toxicity in mice. Eur J Pharm Biopharm. 2009; 72(3):626-9. DOI: 10.1016/j.ejpb.2009.03.007. View

Cho M, Cho W, Choi M, Kim S, Han B, Kim S . The impact of size on tissue distribution and elimination by single intravenous injection of silica nanoparticles. Toxicol Lett. 2009; 189(3):177-83. DOI: 10.1016/j.toxlet.2009.04.017. View

Decuzzi P, Godin B, Tanaka T, Lee S, Chiappini C, Liu X . Size and shape effects in the biodistribution of intravascularly injected particles. J Control Release. 2009; 141(3):320-7. DOI: 10.1016/j.jconrel.2009.10.014. View

Xie G, Sun J, Zhong G, Shi L, Zhang D . Biodistribution and toxicity of intravenously administered silica nanoparticles in mice. Arch Toxicol. 2009; 84(3):183-90. DOI: 10.1007/s00204-009-0488-x. View

Kumar R, Roy I, Ohulchanskky T, Vathy L, Bergey E, Sajjad M . In vivo biodistribution and clearance studies using multimodal organically modified silica nanoparticles. ACS Nano. 2010; 4(2):699-708. PMC: 2827663. DOI: 10.1021/nn901146y. View

10.

Bimbo L, Sarparanta M, Santos H, Airaksinen A, Makila E, Laaksonen T . Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. ACS Nano. 2010; 4(6):3023-32. DOI: 10.1021/nn901657w. View

11.

Dekkers S, Krystek P, Peters R, Lankveld D, Bokkers B, van Hoeven-Arentzen P . Presence and risks of nanosilica in food products. Nanotoxicology. 2010; 5(3):393-405. DOI: 10.3109/17435390.2010.519836. View

12.

Liu T, Li L, Teng X, Huang X, Liu H, Chen D . Single and repeated dose toxicity of mesoporous hollow silica nanoparticles in intravenously exposed mice. Biomaterials. 2010; 32(6):1657-68. DOI: 10.1016/j.biomaterials.2010.10.035. View

13.

He Q, Zhang Z, Gao F, Li Y, Shi J . In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation. Small. 2011; 7(2):271-80. DOI: 10.1002/smll.201001459. View

14.

Huang X, Li L, Liu T, Hao N, Liu H, Chen D . The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. ACS Nano. 2011; 5(7):5390-9. DOI: 10.1021/nn200365a. View

15.

Yu T, Hubbard D, Ray A, Ghandehari H . In vivo biodistribution and pharmacokinetics of silica nanoparticles as a function of geometry, porosity and surface characteristics. J Control Release. 2012; 163(1):46-54. PMC: 3476833. DOI: 10.1016/j.jconrel.2012.05.046. View

16.

De Temmerman P, Van Doren E, Verleysen E, Van der Stede Y, Francisco M, Mast J . Quantitative characterization of agglomerates and aggregates of pyrogenic and precipitated amorphous silica nanomaterials by transmission electron microscopy. J Nanobiotechnology. 2012; 10:24. PMC: 3462150. DOI: 10.1186/1477-3155-10-24. View

17.

Malfatti M, Palko H, Kuhn E, Turteltaub K . Determining the pharmacokinetics and long-term biodistribution of SiO2 nanoparticles in vivo using accelerator mass spectrometry. Nano Lett. 2012; 12(11):5532-8. PMC: 3499105. DOI: 10.1021/nl302412f. View

18.

Fu C, Liu T, Li L, Liu H, Chen D, Tang F . The absorption, distribution, excretion and toxicity of mesoporous silica nanoparticles in mice following different exposure routes. Biomaterials. 2013; 34(10):2565-75. DOI: 10.1016/j.biomaterials.2012.12.043. View

19.

Yu Y, Li Y, Wang W, Jin M, Du Z, Li Y . Acute toxicity of amorphous silica nanoparticles in intravenously exposed ICR mice. PLoS One. 2013; 8(4):e61346. PMC: 3625170. DOI: 10.1371/journal.pone.0061346. View

20.

Liu T, Liu H, Fu C, Li L, Chen D, Zhang Y . Smaller silica nanorattles reabsorbed by intestinal aggravate multiple organs damage. J Nanosci Nanotechnol. 2013; 13(10):6506-16. DOI: 10.1166/jnn.2013.7545. View